Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 161-165

  Villemagne, Victor L ^a,c   Okamura, Nobuyuki ^d   Pejoska, Svetlana ^c   Drago, John ^a,b   Mulligan, Rachel S ^c   Chételat, Gaël ^c,e   O'Keefe, Graeme ^c   Jones, Gareth ^c   Kung, Hank F ^f   Pontecorvo, Michael ^g   Masters, Colin L ^a   Skovronsky, Daniel M ^f,g   Rowe, Christopher C ^c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITÉ DE CAEN   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Dementia with Lewy bodies; Differential diagnosis

Indexed keywords

AMYLOID BETA PROTEIN; FLORBENAZINE F 18; FLORBETABEN; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; ARTICLE; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MALE; MESENCEPHALON; NEUROIMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYGDALA; ANILINE COMPOUNDS; BRAIN MAPPING; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; THIAZOLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84860219799     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000334535     Document Type: Article

References (18)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
2. McKeith IG, Mosimann UP: Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord 2004; 10(suppl 1): S15-S18.
3. Kemp PM, Holmes C: Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007; 28: 511-519.
4. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, et al: 11 C-DTBZ and 18 F-FDG PET measures in differentiating dementias. J Nucl Med 2005; 46: 936-944.
5. Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF: Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007; 34: 239-246.
6. Hefti FF, Kung HF, Kilbourn MR, Carpenter AP, Clark CM, Skovronsky DM: 18 F-AV-133: a selective VMAT2-binding radiopharmaceutical for PET imaging. PET Clin 2010; 5: 75-82.
7. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, et al: In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010; 51: 223-228.
8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, et al: Imaging betaamyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
9. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, et al: Imaging of amyloid beta in Alzheimer's disease with 18 F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-135.
10. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, et al: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [ 11 C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
11. Frey KA, Koeppe RA, Kilbourn MR: Imaging the vesicular monoamine transporter. Adv Neurol 2001; 86: 237-247.
12. Suzuki M, Desmond TJ, Albin RL, Frey KA: Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 2002; 51: 767-771.
13. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI: Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999; 156: 138-148.
14. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR: Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [ 11 C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999; 19: 1376-1384.
15. Martin WR, Wieler M, Stoessl AJ, Schulzer M: Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008; 63: 388-394.
16. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 12245-12250.
17. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622-630.
18. Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, et al: Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010; 9: 1070-1077.